Antares Pharma, Inc.

ATRSCIK 0001016169 · Every Form 4 filed by insiders at this issuer. See financials →

Annual report (10-K)

Latest 10-K/A filed Apr 29, 2022. Sentiment + YoY language diff vs prior year. Read sections →

Signal:NeutralFull-doc fallback

Full filing:tone 0.0014

Sentiment via Loughran-McDonald lexicon · YoY diff via Jaccard similarity + paragraph set difference.

YoY shift: Unscored

Year-over-year tone shift - average net-tone change across Risk Factors and MD&A vs the prior 10-K.

Why YoY instead of absolute: the LM lexicon has ~6.6× more negative words than positive (legal/risk-disclosure language is heavy on hedging), so every 10-K reads bearish on raw tone. Year-over-year change strips that bias and surfaces the actual shift in management's framing.

Per-snippet highlights

Sentence-level sentiment highlighting with category and subcategory filters is coming once the snippet-scoring pipeline lands. For now, dig into the actual section text on the Sections tab.

Top insiders

Most active reporters at Antares Pharma, Inc.

Name	Roles	Filings
Apple Robert F	OfficerDirector	3
Graham Peter J	Officer	3
Powell Fred M	Officer	3
Garrity Thomas J	Director	1
Gueth Anton	Director	1

Showing 1-5 of 11

Per pagePage 1 of 3Next

All filings

17 Form 4 / 4-A filings, newest first

Filed	Insider	Top transaction	Shares	Price	Value
May 26, 2022	Greenleaf Peter Director	DDisposition	49,425	$5.60	$276,780
May 26, 2022	Volkart Carmen B Director	Holdings only	-	-	-
May 26, 2022	Apple Robert F President and CEO · Director	DDisposition	1,876,693	$5.60	$10,509,481
May 26, 2022	Powell Fred M Executive Vice President & CFO	DDisposition	587,014	$5.60	$3,287,278
May 26, 2022	Garrity Thomas J Director	DDisposition	224,406	$5.60	$1,256,674

Showing 1-5 of 17

Per pagePage 1 of 4Next

Real-time Form 4 intelligence. Smarter insider tracking.

Filed		Top transaction	Shares	Price	Value